Taiji Group announced that the company disclosed the main operating data for January-September 2026. The consolidated statement achieved main business revenue of 7.904 billion yuan, a year-on-year decrease of 11.31%; the pharmaceutical industry's main business revenue was 3.387 billion yuan, a year-on-year decrease of 15.87%; the pharmaceutical business was 4.483 billion yuan, a year-on-year decrease of 4.77%; and Chinese herbal medicine resources were 813 million yuan, a year-on-year decrease of 0.89%.

Disclaimer:Webull uses external vendor Google Translation Service for news translations where we endeavour to ensure these are correct, however, we recommend that you please double-check this information accordingly. Webull is not responsible for translation errors or issues.